The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma.

Autor: Pangarsa EA; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia., Naibaho RM; Trainee in Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia.; Department of Internal Medicine, Parikesit Hospital, Mulawarman School of Medicine, Samarinda, East Kalimantan, Indonesia., Yunarvika V; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia., Setiawan B; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia., Santosa D; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia., Suharti C; Subdivion of Hematology and Medical Oncology, Medical Faculty of Diponegoro University, Dr. Kariadi General Hospital, Semarang, Indonesia.
Jazyk: angličtina
Zdroj: Case reports in hematology [Case Rep Hematol] 2021 Nov 03; Vol. 2021, pp. 9632427. Date of Electronic Publication: 2021 Nov 03 (Print Publication: 2021).
DOI: 10.1155/2021/9632427
Abstrakt: Up to 20-40% of patients with Hodgkin's lymphoma will eventually relapse after treatment, among which early relapse confers a poor outcome. With salvage chemotherapy followed by autologous stem cell transplantation (ASCT), the long-term remission rate is 30%. We report our experience of using a modified-BEAM conditioning regimen without BCNU consisting of etoposide, cytarabine, and melphalan (EAM) in a patient with relapsed Hodgkin's lymphoma. Before transplantation, the patient achieved second complete remission (CR2) using brentuximab vedotin and ESHAP (BR-ESHAP) chemotherapy. The ASCT went well without significant complications. This case demonstrated the considerable efficacy of EAM protocol as a conditioning regimen in terms of sufficient ablative capabilities, and the patient showed a successful hematopoietic engraftment. Although durability of the disease-free survival needs further observation, it had nearly 18 months of complete remission and the patient was in good performance status at the time of writing this manuscript.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2021 Eko A. Pangarsa et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje